← Back to Search

Epigenetic Modifiers

Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

Phase 2
Waitlist Available
Led By Edwin Lee, MD
Research Sponsored by TruDiagnostic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to 6 months
Awards & highlights
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

This trial is testing whether Quercetin and Dasatinib supplements can slow down the aging process in healthy people. These supplements are thought to work by slowing down how quickly cells multiply. The goal is to see if this can help people live longer and reduce age-related diseases. Quercetin is a natural flavonoid found in many foods and has been studied for its anti-cancer, anti-inflammatory, and anti-aging effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Examining Methylation changes

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Quercetin and Dasatinib supplementsExperimental Treatment1 Intervention
500mg Quercetin and 50mg Dasatinib oral capsules on Monday, Tuesday, Wednesday (3 days in a row) per month for the duration of 6 months.

Find a Location

Who is running the clinical trial?

TruDiagnosticLead Sponsor
11 Previous Clinical Trials
461 Total Patients Enrolled
8 Trials studying Aging
351 Patients Enrolled for Aging
Edwin Lee, MDPrincipal InvestigatorThe Institute for Hormonal Balance
~5 spots leftby Dec 2025